首页> 外文期刊>Cardiovascular Research >Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates
【24h】

Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates

机译:通过间充质干细胞中间体衍生自人诱导多能干细胞的功能性血管平滑肌细胞

获取原文
获取原文并翻译 | 示例
           

摘要

AimsSmooth muscle cells (SMC) play an important role in vascular homeostasis and disease. Although adult mesenchymal stem cells (MSC) have been used as a source of contractile SMC, they suffer from limited proliferation potential and culture senescence, particularly when originating from older donors. By comparison, human induced pluripotent stem cells (hiPSC) can provide an unlimited source of functional SMC for autologous cell-based therapies and for creating models of vascular disease. Our goal was to develop an efficient strategy to derive functional, contractile SMC from hiPSC.Methods and resultsWe developed a robust, stage-wise, feeder-free strategy for hiPSC differentiation into functional SMC through an intermediate stage of multipotent MSC, which could be coaxed to differentiate into fat, bone, cartilage, and muscle. At this stage, the cells were highly proliferative and displayed higher clonogenic potential and reduced senescence when compared with parental hair follicle mesenchymal stem cells. In addition, when exposed to differentiation medium, the myogenic proteins such as α-smooth muscle actin, calponin, and myosin heavy chain were significantly upregulated and displayed robust fibrillar organization, suggesting the development of a contractile phenotype. Indeed, tissue constructs prepared from these cells exhibited high levels of contractility in response to receptor- and non-receptor-mediated agonists.ConclusionWe developed an efficient stage-wise strategy that enabled hiPSC differentiation into contractile SMC through an intermediate population of clonogenic and multipotent MSC. The high yield of MSC and SMC derivation suggests that our strategy may facilitate an acquisition of the large numbers of cells required for regenerative medicine or for studying vascular disease pathophysiology.
机译:目的平滑肌细胞(SMC)在血管稳态和疾病中起重要作用。尽管成人间充质干细胞(MSC)已被用作收缩性SMC的来源,但它们的增殖潜能和培养衰老能力有限,尤其是当其来自较老的供体时。相比之下,人类诱导的多能干细胞(hiPSC)可以为基于自体细胞的疗法和创建血管疾病模型提供无限的功能性SMC来源。我们的目标是开发一种从hiPSC衍生功能性,收缩性SMC的有效策略。方法和结果我们开发了一种稳健,分阶段,无饲养者的策略,可通过中间多能MSC的中间阶段将hiPSC分化为功能性SMC。区分脂肪,骨骼,软骨和肌肉。在这个阶段,与亲代毛囊间充质干细胞相比,这些细胞具有很高的增殖能力,并显示出更高的克隆形成潜能和衰老降低。此外,当暴露于分化培养基时,α-平滑肌肌动蛋白,钙蛋白和肌球蛋白重链等肌原性蛋白被显着上调,并表现出强健的原纤维组织,表明出现了收缩表型。实际上,由这些细胞制备的组织构建体在响应受体和非受体介导的激动剂时表现出高水平的收缩力。结论我们开发了一种有效的分阶段策略,可通过中间克隆和多能MSC群体使hiPSC分化为收缩性SMC。 。 MSC和SMC衍生的高产率表明,我们的策略可能有助于获取再生医学或研究血管疾病病理生理学所需的大量细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号